The Claim
Daily administration of 100 mg enteric-coated aspirin does not significantly reduce the risk of a composite cardiovascular disease endpoint (including fatal or nonfatal coronary events, stroke, or heart failure hospitalization) in healthy community-dwelling adults aged 70 years and older.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a daily 100 mg aspirin pill does not actually lower the chance of heart attacks, strokes, or heart failure in healthy seniors over 70. A recent study showed that older adults who took aspirin had almost the same number of heart events as those who took a placebo.
See the scientific wording
Daily administration of 100 mg enteric-coated aspirin does not significantly reduce the risk of cardiovascular disease, defined as a composite of fatal coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart failure, in healthy community-dwelling adults aged 70 years and older. Over a median follow-up of 4.7 years, the event rate was 10.7 per 1000 person-years in the aspirin group versus 11.3 per 1000 person-years in the placebo group, yielding a hazard ratio of 0.95 (95% CI 0.83 to 1.08), indicating no clinically meaningful protective effect in this demographic.
What the research says
1 studyStudy: Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
The RCT directly compared aspirin to placebo in a large cohort of healthy elderly adults. The hazard ratio crossing 1.0 and the p-value not reaching significance demonstrate no causal reduction in cardiovascular events.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.